Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Preventive Treatment of Episodic Migraine in Pediatric Patients
NCT04458857Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in episodic migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Monthly Migraine Days at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
fremanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT04458857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458857.